What’s cooking in the IPO kitchen?
Filta— Schedule One from the provider of a number of services to national and independent commercial kitchen operators and owners.
Targets early November listing. Capital raising plans as yet undisclosed
TI Van Elle—The geotechnical contractor to the UK construction market is hoping to come to AIM later this month
Ascot Lloyd— The UK IFA is also hoping to join AIM later this month. Ascot Lloyd's strategy is to grow through a combination of organic growth and further targeted acquisitions.
Breakfast buffet
Fusionex International (LON:FXI) 175p £82.78m
FYSep16 trading update from the multi-award winning international software solutions provider specialising in Big Data Analytics, Artificial Intelligence and the Internet of Things. Building on momentum achieved H1, Fusionex has continued to deliver on its strategy and make progress throughout the year. In particular, the Group successfully launched the next generation of its proprietary Big Data Analytics ("BDA") platform, 'GIANT 2016', in June 2016. Revenue expected in-line and EBITDA significantly ahead. FY16E rev £17.05m, Pre-tax loss £1.49m.
Rex Bionics (LON:RXB) 22.5p £5.74m
The pioneer of the REX Robot technology that enhances the mobility of wheelchair users, has announced the start of a new clinical trial treating patients who have had a stroke or brain injury, with Robot-Assisted Physiotherapy with REX. Trish Leonard, the Founder of the Australian Institute of Neuro-rehabilitation, commented: "In REX's self-supporting exoskeleton we see the potential to provide greater opportunities for weight bearing exercises to people with stroke and other acquired brain injuries. “
Crossrider (LON:CROS) 35p £49.37m
The online distribution and digital product company, today announced the expansion of its app distribution business with the acquisition of PC maintenance software product, DriverAgent, from eSupport.com, Inc. for a Total consideration of $1 million. In line with Crossrider's new strategy to strengthen the Group's B2C reach allowing it to operate as a digital distribution and product hub utilising its existing technology and intellectual property. DriverAgent has already been a success on the platform. FYDec16E rev £45.86m, EPS 2.32p.
Cerillion (LON:CER) 130.5p £38.5m
The billing, charging and customer relationship management software solutions provider, has been positioned in the "Visionaries" quadrant of Gartner's recently published report, "Magic Quadrant for Integrated Revenue and Customer Management (IRCM) for CSPs “ (Communications Service Providers). Gartner is the world's leading information technology research and advisory company. Also in-line trading update for FYSEP16. Revenues and EBITDA for the year are expected to show respective increases of 6% to £14.8m and 8% to £3.1m.
Sunrise Resources (LON:SRES) 0.22p £2.41m
The diversified mineral exploration and development company, announced results of the second phase of drilling at its Bay State Silver Project in Nevada together with the results of a small programme of underground sampling, both targeting extensions of the Chihuahua Vein system south of Mining Canyon. Shallow underground (near surface) samples include 0.91m grading 480 grammes/ tonne silver. Hole 16SRRC004 - Located Chihuahua Vein system at c.300m below surface. Another hole stopped short of this vein. A third did not intersect the Lincoln Vein.
Premier Asset Management Group (LON:PAM) 134.5p £142.3m
Q4 30Sep trading update. Total AUM increased to £5 billion as at 30 September 2016. Total net inflows over the year of £778m. Net inflows over the quarter ended 30 September 2016 of £95m. Over a three and five year period, 96% and 94% respectively of Premier's retail fund AUM were above median, with 71% and 73% of Premier's retail fund AUM achieving first quartile performance in their respective IA sector over the same time periods (excluding absolute return and volatility targeted funds).
Faron Pharma (LON:FARN) 255p £67.09m
The clinical stage biopharmaceutical company, announced that its Japanese licensing partner Maruishi Pharmaceutical Co., Ltd. has recruited the first patient in the Japanese Phase III pivotal clinical trial for the treatment of acute respiratory distress syndrome ("ARDS") with FP-1201-lyo (also known as Traumakine®). ARDS is a severe orphan disease with a reported mortality rate of approximately 30-45%, for which there is currently no approved pharmacological treatment. Earlier trials have shown a significant decrease in mortality.
Frontera Resources Corp(LON:FRR) 0.09p £6.76m
The oil and gas exploration and production company has released an update of its operations in the country of Georgia. Following extensive workover operations throughout October, six new wells have now been prepared and will shortly receive stimulation completions in November. The Company expects that the upcoming campaign will significantly contribute towards its current objective of achieving overall year-end pilot production rates of 2,200boe per day, which would result in monthly revenues of approximately $3m at current commodity prices.